← Retour à la une
États-Unis · Agences & temps réel · PR Newswire

Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer

Publié par PR Newswire · États-Unis il y a 2 h
Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer
PR Newswire

Résumé détaillé

HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted…

The sNDA is supported by results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-GI1 study (AK112-309). The study evaluated ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy, a current global standard of care for first-line BTC. At a pre-specified interim analysis, the study met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement. All key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR), were also met.

HARMONi-GI1 is the first Phase III study in biliary tract cancer to demonstrate a statistically significant overall survival benefit versus a PD-L1 inhibitor plus chemotherapy regimen. The results were presented as a Late-Breaking Abstract in an oral presentation at the ESMO Presidential Symposium in October 2026.

The global registrational development of ivonescimab in biliary tract cancer is progressing. The Phase II/III study EA2251, conducted in collaboration with Summit Therapeutics, and the ECOG-ACRIN Cancer Research Group, has been initiated. This study will evaluate ivonescimab plus chemotherapy versus pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of advanced BTC. EA2251 represents the seventh international registrational clinical trial of ivonescimab.

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

À lire aussi